Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

Summary

This study is a two-part Phase 1b/2a First-in-Human (FIH) randomized, double-blind, placebo-controlled clinical trial to assess the safety, tolerability, pharmacodynamics, and efficacy of multiple ascending doses of CNP-201 in Part A, with the goal of identifying a safe and tolerable dose level to be evaluated further in a larger number of subjects in Part B.

Timeline

Start

2021-06-02

Primary completion

2022-06-24

Completion

2022-07-29

Outcome

Outcome not reported

Stopped (Enrollment): “Lagging Enrollment. Opened a separate study.”

Drugs

Indications